Skip to main content
Publications
Goyal RK , Cuyun Carter G, Nagar SP , Nash Smyth E, Price GL, Parikh RC , Huang YJ, Li L, Davis KL , Kaye JA. Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2- metastatic breast cancer in the United States . Expert Rev Pharmacoecon Outcomes Res. 2021;21(4):699-710. doi: 10.1080/14737167.2020.1804871
Samelson EJ, Miller PD, Christiansen C, Daizedeh NS, Grazette L, Anthony MS , Egbuna O, Wang A, Siddhanti SR, Cheung AM, Franchimont N, Kiel DP. RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk . J Bone Miner Res. 2014 Feb;29(2):450-7. doi: 10.1002/jbmr.2043
Khalil S, Rodarte A, Weldon BC, Weinstein M, Grunwald Z, Ginsberg B, Kaye R, Otto A, Wheeler M, Lawhorn CD, Prillaman BA , Creed M. Intravenous ondansetron in established postoperative emesis in children. S3A-381 study group . Anesthesiology. 1996 Aug;85(2):270-6. doi: 10.1097/00000542-199608000-00007